Henry Schein, Inc. $HSIC Shares Sold by Olstein Capital Management L.P.

Olstein Capital Management L.P. reduced its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 11.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 89,000 shares of the company’s stock after selling 11,000 shares during the quarter. Henry Schein comprises 1.4% of Olstein Capital Management L.P.’s portfolio, making the stock its 26th largest holding. Olstein Capital Management L.P.’s holdings in Henry Schein were worth $6,727,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. MAI Capital Management boosted its stake in Henry Schein by 7.5% during the third quarter. MAI Capital Management now owns 2,061 shares of the company’s stock valued at $137,000 after buying an additional 144 shares in the last quarter. Truist Financial Corp raised its position in Henry Schein by 3.3% in the third quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock worth $368,000 after acquiring an additional 175 shares in the last quarter. HB Wealth Management LLC raised its position in Henry Schein by 1.3% in the fourth quarter. HB Wealth Management LLC now owns 15,034 shares of the company’s stock worth $1,136,000 after acquiring an additional 191 shares in the last quarter. Czech National Bank lifted its holdings in Henry Schein by 0.8% in the 4th quarter. Czech National Bank now owns 26,386 shares of the company’s stock valued at $1,994,000 after acquiring an additional 206 shares during the last quarter. Finally, Jain Global LLC lifted its holdings in Henry Schein by 2.0% in the 3rd quarter. Jain Global LLC now owns 10,662 shares of the company’s stock valued at $708,000 after acquiring an additional 207 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Insiders Place Their Bets

In other Henry Schein news, EVP Mark E. Mlotek sold 5,925 shares of Henry Schein stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $80.80, for a total transaction of $478,740.00. Following the transaction, the executive vice president directly owned 80,554 shares in the company, valued at approximately $6,508,763.20. The trade was a 6.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Kurt P. Kuehn sold 2,844 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total transaction of $224,562.24. Following the sale, the director directly owned 15,420 shares in the company, valued at approximately $1,217,563.20. This trade represents a 15.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 105,911 shares of company stock worth $8,574,982 in the last quarter. Corporate insiders own 0.89% of the company’s stock.

Henry Schein Trading Down 2.7%

Shares of HSIC opened at $70.50 on Friday. The business’s 50-day moving average price is $76.06 and its 200 day moving average price is $75.05. The company has a current ratio of 1.36, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $8.09 billion, a P/E ratio of 21.30, a P/E/G ratio of 1.82 and a beta of 0.82. Henry Schein, Inc. has a 1-year low of $61.94 and a 1-year high of $89.29.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The company had revenue of $3.37 billion during the quarter, compared to analyst estimates of $3.34 billion. During the same period in the prior year, the firm earned $1.15 earnings per share. The business’s quarterly revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Analysts expect that Henry Schein, Inc. will post 5.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on HSIC shares. Wall Street Zen cut shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Wells Fargo & Company increased their target price on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 25th. Morgan Stanley restated an “underweight” rating and set a $64.00 target price (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. UBS Group restated a “neutral” rating and issued a $85.00 price target (down from $87.00) on shares of Henry Schein in a research report on Wednesday. Finally, BTIG Research assumed coverage on Henry Schein in a report on Thursday, April 16th. They issued a “neutral” rating on the stock. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $86.83.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.